Trial Profile
Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs BMS 986218 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 21 Mar 2024 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 02 Jan 2024 Planned primary completion date changed from 10 Dec 2023 to 12 Apr 2024.
- 12 May 2023 This trial has been completed in Poland, according to European Clinical Trials Database record.